Effect of sputum bacteriology on the quality of life of patients with bronchiectasis

Bronchiectatic patients have impaired health-related quality of life (QoL) and are prone to chronic lower respiratory tract infections. We have investigated whether impaired QoL is related to sputum bacteriology. Eighty seven patients with non-cystic fibrosis (non-CF) bronchiectasis, in a stable phase of their illness, completed three QoL measures, underwent a computed tomography (CT) scan and lung function tests, and provided a fresh sputum sample for microscopy and culture. The QoL of patients colonized by Pseudomonas aeruginosa (Pa group) was significantly worse than all other patients grouped together (non-Pa group), and specifically those infected by Haemophilus influenzae (Hi group) or who had no bacterial growth (NG group) (p<0.05), but not those infected by other bacterial species (O group). The Pa group had worse lung function, but no significant differences were found between the groups for forced expiratory volume in one second (FEV1) and peak expiratory flow rate. The Pa group had significantly worse bronchiectasis scores than the O, NG and non-Pa groups, but not the Hi group. There were no significant differences between the groups with respect to the number of infective exacerbations in the last year, but the Pa group had significantly more hospital admissions. Patients infected by P. aeruginosa for more than 3 yrs had significantly worse FEV1 (p<0.03) and bronchiectasis scores (p<0.05) than those infected with P. aeruginosa for less time, but not significantly worse QoL. We conclude that, overall, patients infected with P. aeruginosa have worse quality of life, and that P. aeruginosa is associated with a greater extent of disease and worse lung function. Although patients infected with H. influenzae had extensive bronchiectasis their quality of life was better than the P. aeruginosa infected group.

This article has been cited by other articles:

				M. P. Murray, J. L. Pentland, K. Turnbull, S. MacQuarrie, and A. T. Hill Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis Eur. Respir. J., August 1, 2009; 34(2): 361 - 364. [Abstract] [Full Text] [PDF]

				M. P. Murray, K. Turnbull, S. MacQuarrie, J. L. Pentland, and A. T. Hill Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis Eur. Respir. J., July 1, 2009; 34(1): 125 - 131. [Abstract] [Full Text] [PDF]

				M. P. Murray, K. Turnbull, S. MacQuarrie, and A. T. Hill Assessing response to treatment of exacerbations of bronchiectasis in adults Eur. Respir. J., February 1, 2009; 33(2): 312 - 318. [Abstract] [Full Text] [PDF]

				B. Ryall, J. C. Davies, R. Wilson, A. Shoemark, and H. D. Williams Pseudomonas aeruginosa, cyanide accumulation and lung function in CF and non-CF bronchiectasis patients Eur. Respir. J., September 1, 2008; 32(3): 740 - 747. [Abstract] [Full Text] [PDF]

				J. Courtney, M. Kelly, A Watt, L Garske, J Bradley, M Ennis, and J. Elborn Quality of life and inflammation in exacerbations of bronchiectasis Chronic Respiratory Disease, August 1, 2008; 5(3): 161 - 168. [Abstract] [PDF]

				A B Chang and D Bilton Exacerbations in cystic fibrosis: 4 {middle dot} Non-cystic fibrosis bronchiectasis Thorax, March 1, 2008; 63(3): 269 - 276. [Abstract] [Full Text] [PDF]

				G. Davies, A. U. Wells, S. Doffman, S. Watanabe, and R. Wilson The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Eur. Respir. J., November 1, 2006; 28(5): 974 - 979. [Abstract] [Full Text] [PDF]

				D. Bilton, N. Henig, B. Morrissey, and M. Gotfried Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis. Chest, November 1, 2006; 130(5): 1503 - 1510. [Abstract] [Full Text] [PDF]

				M. D. Macia, N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa Antimicrob. Agents Chemother., March 1, 2006; 50(3): 975 - 983. [Abstract] [Full Text] [PDF]

				M. J. Rosen Chronic Cough Due to Bronchiectasis: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 122S - 131S. [Abstract] [Full Text] [PDF]

				M. D. Macia, D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3382 - 3386. [Abstract] [Full Text] [PDF]

				A. M. Li, S. Sonnappa, C. Lex, E. Wong, A. Zacharasiewicz, A. Bush, and A. Jaffe Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur. Respir. J., July 1, 2005; 26(1): 8 - 14. [Abstract] [Full Text] [PDF]

				P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis Chest, April 1, 2005; 127(4): 1420 - 1426. [Abstract] [Full Text] [PDF]

				M E. Drobnic, P. Sune, J B. Montoro, A. Ferrer, and R. Orriols Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa Ann. Pharmacother., January 1, 2005; 39(1): 39 - 44. [Abstract] [Full Text] [PDF]

				S. L. Chan, M. M. Chan-Yeung, G. C. Ooi, C. L. Lam, T. F. Cheung, W. K. Lam, and K. W. Tsang Validation of the Hong Kong Chinese Version of the St. George Respiratory Questionnaire in Patients With Bronchiectasis Chest, December 1, 2002; 122(6): 2030 - 2037. [Abstract] [Full Text] [PDF]

				M. Ferrer, C. Villasante, J. Alonso, V. Sobradillo, R. Gabriel, G. Vilagut, J.F. Masa, J.L. Viejo, C.A. Jimenez-Ruiz, and M. Miravitlles Interpretation of quality of life scores from the St George's Respiratory Questionnaire Eur. Respir. J., March 1, 2002; 19(3): 405 - 413. [Abstract] [Full Text] [PDF]

				E Caballero, M-E Drobnic, M-T Perez, J-M Manresa, A Ferrer, and R Orriols Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis Thorax, September 1, 2001; 56(9): 669 - 674. [Abstract] [Full Text] [PDF]

				L. A. Couch Treatment With Tobramycin Solution for Inhalation in Bronchiectasis Patients With Pseudomonas aeruginosa Chest, September 1, 2001; 120 (2009): 114S - 117S. [Abstract] [Full Text] [PDF]

				A. F. BARKER, L. COUCH, S. B. FIEL, M. H. GOTFRIED, J. ILOWITE, K. C. MEYER, A. O'DONNELL, S. A. SAHN, L. J. SMITH, J. O. STEWART, et al. Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in Bronchiectasis Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 481 - 485. [Abstract] [Full Text] [PDF]

				R. Wilson and R. B Dowling Pseudomonas aeruginosa and other related species Thorax, March 1, 1998; 53(3): 213 - 219. [Full Text]